Our demonstration that Type I IFNs mediate their anti-melanoma effects, at least in part, by inhibiting the Sema7a-Chi3l1 pathway raises the interesting possibility that the Sema7a-Chi3l1 axis plays an important role in the immunoediting response. This evidence concerns the gene SEMA7A and melanoma.